Simultaneous Applications Submitted to EMA and FDA for Siltuximab for the Treatment of Multicentric Castleman Disease, a Rare Blood Disorder
- EMEA Innovative Medicine
- Simultaneous Applications Submitted for Siltuximab to Treat Multicentric Castleman Disease
Simultaneous Applications Submitted for Siltuximab to Treat Multicentric Castleman Disease
- X (Twitter)
Copy link